Dr. Plimack on Strategies for Developing Cure for Locally Advanced Urothelial Carcinoma

Video

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses strategies for developing cures for patients with locally advanced urothelial carcinoma.

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses strategies for developing cures for patients with locally advanced urothelial carcinoma.

Locally advanced bladder cancer has made its way into the muscle of the bladder but hasn’t extended beyond that, explains Plimack. It is a high-risk situation where, if left untreated, many patients would progress to metastatic disease. It also presents an opportunity for cure and many researchers are developing the best strategies to increase the cure rate for these patients.

Neoadjuvant cisplatin-based chemotherapy is proven to improve the cure rate and extend survival in this group, states Plimack. However, there is ongoing biomarker research that is looking to see which patients will benefit the most and can keep their bladder.

Related Videos
Rita Nanda, MD
Vikram Narayan, MD
Daniel Olson, MD
Vishal Patel, MD, FAAD, FACMS, associate professor, Dermatology, George Washington (GW) School of Medicine & Health Sciences
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS